News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

April 22, 2024

Lipidor AB announces new date for publication of Annual Report 2023

Lipidor AB (publ) today announces that the Board of Directors has resolved to postpone the publication of the Annual Report for 2023 to 15 May 2024. The previously communicated date for publication was 24 April 2024. The reason for the postponement is to synchronise the Annual Report work with the…

April 10, 2024

NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Extraordinary General Meeting (the…

April 10, 2024

Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW…

March 26, 2024

Lipidor completes planned divestment of shares in Emollivet

STOCKHOLM, Sweden, 26th March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the remaining holding of…

March 21, 2024

Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2

STOCKHOLM, Sweden, 21st March 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the company's planned Phase…

March 6, 2024

Lipidor adds capital through sale of shares

STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding…

February 28, 2024

Lipidor AB (publ) publishes year-end report for 2023

STOCKHOLM, Sweden, 28th February 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the…

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's…

December 21, 2023

Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan

STOCKHOLM, Sweden, 21st December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that 63 shares, corresponding to…

December 20, 2023

Lipidor applies to the Indian Medical Products Agency to start a Phase III study of AKP02G2

STOCKHOLM, Sweden, 20th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company, through its…

December 5, 2023

Lipidor presents Nomination Committee

STOCKHOLM, Sweden, 5th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today presents its Nomination Committee, which shall…